Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

SPECTATOR: Perfusion Monitoring Before, During and After Lower Extremity Revascularization With Laser Speckle Contrast Imaging (SPECTATOR)

9 de septiembre de 2026 actualizado por: Joost R. van der Vorst, MD, PhD, Leiden University Medical Center
This study aims to evaluate the feasibility of Laser Speckle Contrast Imaging for perioperative perfusion assessment of the lower extremity before, during, and after revascularization.

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

Rationale: Lower extremity arterial disease (LEAD) arises from atherosclerotic obstruction in the lower limbs, which in turn leads to symptoms ranging from intermittent claudication to ulcer formation. As the disease progresses, patients often require revascularization to achieve limb salvage.

To improve prediction of clinical outcomes following revascularization, various techniques have been introduced to quantify tissue perfusion. Among these, near-infrared fluorescence imaging with indocyanine green (ICG NIRF) has gained attention. This method combines a laser light source with intravenous ICG administration to visualize perfusion. Although ICG NIRF appears promising for guiding revascularization strategies and predicting outcomes, its invasive nature, requiring dye injection, limits its use in outpatient settings.

Consequently, there is a need for a non-invasive, real-time technique that enables rapid and straightforward perfusion assessment. One such promising approach is laser speckle contrast imaging (LSCI). Therefore, this study aims to evaluate the feasibility of LSCI for perioperative perfusion assessment of the lower extremity before, during, and after revascularization.

Objective:The primary objective of this study is to evaluate the feasibility of laser speckle contrast imaging (LSCI) for monitoring perfusion in the lower extremities during and following revascularization.

Secondary objectives include correlating LSCI findings with the temperature of the patient's foot, comparing LSCI with near-infrared fluorescence imaging using indocyanine green (ICG NIRF) and exploring potential quantitative approaches such as the assessment of blood flow pulsatility.

Study design: This study will be a prospective cohort study. Study population: Adult patients undergoing a revascularization of the lower extremity due to peripheral artery disease. Such revascularization can be bypass surgery, thrombo-endarterectomy (TEA), or endovascular percutaneous transluminal angioplasty (PTA).

Intervention: Patients will undergo peri-operative and post-operative LSCI.

Main study parameters/endpoints: The main study parameters are the quantified perfusion parameters measured with LSCI.

Nature and extent of the burden and risks associated with participation. The use of the LSCI device is not expected to cause any adverse effects, as it employs a low-intensity near-infrared laser to illuminate the skin. The photon energy and illumination power used are well below levels that could cause tissue damage and are therefore considered safe for human skin. All measurements are performed alongside standard assessments or routine outpatient clinic appointments. The intraoperative measurement does not extend the duration of the surgical procedure. Given the short duration of each measurement (5-10 seconds), no additional burden on patients is anticipated.

Tipo de estudio

De observación

Inscripción (Estimado)

30

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • South Holland
      • Leiden, South Holland, Países Bajos, 2333ZA
        • Reclutamiento
        • Leiden University Medical Center
        • Contacto:
          • Indy Planting, MD
          • Número de teléfono: +31614524783
          • Correo electrónico: i.planting@lumc.nl
        • Contacto:
        • Sub-Investigador:
          • Indy Planting, MD
        • Investigador principal:
          • Joost van der Vorst, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra de probabilidad

Población de estudio

The population of this study will undergo a revascularization of the lower extremity due to peripheral artery disease. Such revascularization can be thrombo-endarterectomy (TEA), or endovascular percutaneous transluminal angioplasty (PTA).

Descripción

Inclusion Criteria:

  • Scheduled for lower-extremity revascularization
  • Undergoing pre- and postoperative indocyanine near-infrared fluorescence perfusion measurements

Exclusion Criteria:

Any condition that the investigator considers to be potentially jeopardizing the patient's wellbeing or the study objectives

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Fontaine 2
Measurement with LSCI device
Fontaine 3
Measurement with LSCI device
Fontaine 4
Measurement with LSCI device

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To assess the feasibility and the quantification of laser speckle contrast imaging for monitoring of perfusion of the lower extremities during and following revascularization
Periodo de tiempo: From pre-operative baseline measurement through the 6-week postoperative follow-up visit
Feasibility
From pre-operative baseline measurement through the 6-week postoperative follow-up visit

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Correlation of pre-, intra- and postsurgery laser speckle contrast imaging (LSCI) findings with the pre-, intra- and post-temperature of the patient's foot
Periodo de tiempo: From pre-operative baseline measurement through the 6-week postoperative follow-up visit
Temperature
From pre-operative baseline measurement through the 6-week postoperative follow-up visit
Comparative analysis of LSCI with standard of care near-infrared fluorescence imaging using ICG
Periodo de tiempo: From pre-operative baseline measurement through the postoperative ICG-measurement
ICG
From pre-operative baseline measurement through the postoperative ICG-measurement
Exploration of quantitative approaches to LSCI analysis, including assessment of blood flow pulsatility
Periodo de tiempo: From pre-operative baseline measurement through the 6-week postoperative follow-up visit
From pre-operative baseline measurement through the 6-week postoperative follow-up visit
Correlation of quantified LSCI recordings to clinical outcomes.
Periodo de tiempo: 6 weeks postoperative
6 weeks postoperative
Effect of anesthesia induction on quantified LSCI perfusion values
Periodo de tiempo: Intraoperative, pre-anesthesia induction and post-anesthesia induction (prior to revascularization)
Exploratory comparison of quantified laser speckle perfusion units (LSPU) in the plantar region of interest measured before versus after induction of anesthesia (prior to revascularization), to assess whether anesthesia induction is associated with a change in LSCI-derived perfusion values. Measurement setup and non-invasive LSCI acquisition procedure are unchanged from the pre-anesthesia measurement; no additional burden or risk to participants.
Intraoperative, pre-anesthesia induction and post-anesthesia induction (prior to revascularization)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de septiembre de 2026

Finalización primaria (Estimado)

1 de mayo de 2028

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

23 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de abril de 2026

Publicado por primera vez (Actual)

30 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

14 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir